Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist

Documents similaires

• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  par: Carel W. le Roux, et autres
  Publié: (2024)
• Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
  par: Claire H. Parker, et autres
  Publié: (2025)
• Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
  par: W. Timothy Garvey, et autres
  Publié: (2024)
• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  par: Faisal I. Almohaileb, et autres
  Publié: (2025)
• Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
  par: Sean Wharton, et autres
  Publié: (2024)